News About: Pharm. Industry
Reliability and preference towards generics took a step backwards
It is surveyed that doctors’ reliability and preference towards generic products have not been improved for the past 4 year. Despite effort of domestic pharmaceutical companies and the government to improve images of ...
The highest benefited pharmaceutical company was ‘Pfizer’ last year, followed by ‘Daewoong’Among the 20 pharmaceutical companies with the highest prescription pharmaceutical products benefited by the National Health Insurance, the top one has been known to be ‘Pfizer ...
|
The top 50 pharmaceutical companies occupies 70.3% of the total prescriptions
According to market fluctuation of pharmaceutical products benefited by the National Health Insurance for the past 5 years(2010-2014), the top 50 pharmaceutical companies have shown high concentration with 70.3% of th...
Hanmi started to develop the first generic of Nexavar, a targeted anti-cancer drugHanmi Pharm has begun to develop the first generic of Nexavar(generic name: sorafenib), a liver cancer treatment.
According to the Ministry of Food and Drug Safety on the 16th,...
|
The National Health Insurance partially won the lawsuit against GSK and Dong-A ST
It was ruled that the National Health Insurance budget wasted and reduced by price-fixing among pharmaceutical companies needs to be compensated by the pharmaceutical companies to the National Health Insurance Service...
Dong-A ST has begun to develop a new improved drug avoiding the patent of VireadAs Dong-A ST has acquired approval to conduct a clinical study for a new improved drug of the blockbuster hepatitis B treatment, Viread(generic name: tenofovir) and started its ...
|
The last year’s health insurance benefit was KRW 13.4 trillion, increasing 3.2 times up in 14 years
It is observed that medicine cost of the national health insurance increased 3.2 times higher than the one 14 years ago.
According to the ‘Combined Reports of the 2014 Health Insurance Propriety Assessment Result,’ u...
Huge increase of foreign CROs threaten domestic companies in the domestic clinical study market
In the recent domestic clinical study market, market share of foreign CRO companies have made significant increases, threatening domestic CROs.
In particular, CRAs, key human resources in the market, prefer foreign c...
Domestic pharmaceutical companies busy calculating profit and loss of the Chinese Yuan depreciation
As China dropped the value of Yuan drastically, domestic companies having business relationship with China have been busy calculating profit and loss lately.
According to the industry concern on the 11th, domestic ph...
Celltrion’s ‘Remsima’ acquired the Australian approvalCelltrion announced on the 10th that the company has acquired approval for Remsima from the Australian food and drug ministry, TGA(Therapeutic Goods Administration).
The TGA is...
|
